What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.84%Below 5Y avg (1.90%)
Annual Rate
CNY 0.35Paid annual
Payout Ratio
80.4%Moderate
Payback Period
58.6 yr
Last Ex-Dividend
Jun 25, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
11.88BCNY
1.77B · vs all stocks (USD)
Updated Sep 20, 2026
Trailing P/E
43.20x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Revenue (TTM)
9.93BCNY
1.48B · vs all stocks (USD)
Updated Sep 20, 2026
Profit Margin
2.68%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Beta
0.6980x
vs all stocks
Updated Sep 20, 2026
52-Week Change
18.44%
vs all stocks
Updated Sep 20, 2026
Market Capitalization
11.88BCNY
1.77B · vs all stocks (USD)
Updated Sep 20, 2026
Enterprise Value
13.99BCNY
2.09B · vs all stocks (USD)
Updated Sep 20, 2026
Trailing P/E
43.20x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Forward P/E
29.02x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Price to Sales (TTM)
1.20x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Price to Book (MRQ)
1.79x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Enterprise to Revenue
1.41x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Enterprise to EBITDA
12.66x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 15.87×.Updated Sep 20, 2026
Gross Margin
30.70%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Profit Margin
2.68%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Operating Margin
12.31%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Return on Assets (TTM)
3.64%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Return on Equity (TTM)
4.47%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Revenue (TTM)
9.93BCNY
1.48B · vs all stocks (USD)
Updated Sep 20, 2026
Revenue per Share (TTM)
16.27CNYUpdated Sep 20, 2026
Quarterly Revenue Growth
-1.70%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Gross Profit (TTM)
2.91BCNY
433.79M · vs all stocks (USD)
Updated Sep 20, 2026
EBITDA (TTM)
881.55MCNY
131.54M · vs all stocks (USD)
Updated Sep 20, 2026
Net Income (TTM)
266.13MCNY
39.71M · vs all stocks (USD)
Updated Sep 20, 2026
Quarterly Earnings Growth (YoY)
437.00%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Operating Cash Flow (TTM)
2.01BCNY
299.94M · vs all stocks (USD)
Updated Sep 20, 2026
Levered Free Cash Flow (TTM)
1.58BCNY
236.11M · vs all stocks (USD)
Updated Sep 20, 2026
Trailing Annual Dividend Rate
0.3500CNYUpdated Sep 20, 2026
Trailing Annual Dividend Yield
1.84%
vs all stocks
Updated Sep 20, 2026
5-Year Average Dividend Yield
1.90%
vs all stocks
Updated Sep 20, 2026
Payout Ratio
80.37%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Minority Interest (Equity)
2.16BCNYFY2025 · Dec 31, 2025
Revenue
10.10BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
7.22BCNYFY2025 · Dec 31, 2025
Gross Profit
2.87BCNYFY2025 · Dec 31, 2025
Operating Income
741.48MCNY
110.64M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
256.19MCNYFY2025 · Dec 31, 2025
Income Tax Expense
110.58MCNYFY2025 · Dec 31, 2025
Net Income
145.61MCNYFY2025 · Dec 31, 2025
EBIT
417.65MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
1.20BCNYFY2025 · Dec 31, 2025
Research & Development
254.54MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
649.53MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
67.20MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
24.34MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
161.46MCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.0721CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.0721CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
610.99MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
610.99MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
145.61MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
-101.55MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
1.69BCNYFY2025 · Dec 31, 2025
Free Cash Flow
1.43BCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
2.10BCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
145.61MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
283.39MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
1.28BCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-16.28MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-256.99MCNYFY2025 · Dec 31, 2025
Net Acquisitions
627.75KCNYFY2025 · Dec 31, 2025
Purchase of Investments
-654.40MCNYFY2025 · Dec 31, 2025
Sale of Investments
585.20MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-325.57MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
1.46BCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-2.27BCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-255.80MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-196.23MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-1.26BCNYFY2025 · Dec 31, 2025
Shares Outstanding
624.98MSharesUpdated Sep 20, 2026
Float Shares
426.90MSharesUpdated Sep 20, 2026
% Held by Insiders
30.04%
vs all stocks
Updated Sep 20, 2026
% Held by Institutions
8.03%
vs all stocks
Updated Sep 20, 2026
Total Cash (MRQ)
1.93BCNY
288.48M · vs all stocks (USD)
Updated Sep 20, 2026
Total Cash per Share (MRQ)
3.16CNYUpdated Sep 20, 2026
Total Debt (MRQ)
2.21BCNY
330.40M · vs all stocks (USD)
Updated Sep 20, 2026
Total Debt to Equity (MRQ)
0.2580x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Current Ratio (MRQ)
2.66x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Book Value per Share (MRQ)
10.62CNYUpdated Sep 20, 2026
Total Assets
14.42BCNY
2.15B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
10.86BCNYFY2025 · Dec 31, 2025
Total Liabilities
5.82BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
3.56BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
1.73BCNYFY2025 · Dec 31, 2025
Total Current Liabilities
4.09BCNYFY2025 · Dec 31, 2025
Cash
2.10BCNYFY2025 · Dec 31, 2025
Cash Equivalents
7.36MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
2.11BCNYFY2025 · Dec 31, 2025
Other Short-term Investments
444.45MCNYFY2025 · Dec 31, 2025
Accounts Receivable
5.94BCNYFY2025 · Dec 31, 2025
Inventory
1.55BCNYFY2025 · Dec 31, 2025
Accounts Payable
1.65BCNYFY2025 · Dec 31, 2025
Short-term Debt
1.51BCNYFY2025 · Dec 31, 2025
Other Current Liabilities
30.73MCNYFY2025 · Dec 31, 2025
Long-term Debt
1.15BCNYFY2025 · Dec 31, 2025
Common Stock (Book)
624.98MCNYFY2025 · Dec 31, 2025
Retained Earnings
3.89BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
8.60BCNY
1.28B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
199.57MCNYFY2025 · Dec 31, 2025
52-Week Low
14.48CNYUpdated Sep 20, 2026
52-Week High
33.30CNYUpdated Sep 20, 2026
52-Week Change
18.44%
vs all stocks
Updated Sep 20, 2026
Beta
0.6980x
vs all stocks
Updated Sep 20, 2026
50-Day MA
18.76CNYUpdated Sep 20, 2026
200-Day MA
19.71CNYUpdated Sep 20, 2026
Avg 10-Day Volume
23.37MSharesUpdated Sep 20, 2026
Avg 30-Day Volume
29.53MSharesUpdated Sep 20, 2026
Diluted EPS (TTM)
0.4400CNYUpdated Sep 20, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.